The CellPraxis® Bioengeneering is a company that operates in the Regenerative Medicine, translating research into new treatment options.

The company is part of the Axis Biotec Group, with extensive background in R, D & I (Research, Development and Innovation) and expertise in translating scientific research into safe and commercially viable therapeutic options.

On the platform of the company, the expertise in regulatory areas, project management, intellectual property strategy provides greater efficiency with lower relative cost, representing gains due to synergy and reduction of invested capital.

The CellPraxis® is a bioengineering company that aims to launch innovative products and services in regenerative medicine and cell therapy.

The launch of products and services for orphan conditions or those without therapeutic options is an excellent opportunity.

MISSION

To find, develop and deliver innovative, effective and safe treatment options in cell therapy, benefiting thousands of patients and directly increasing their longevity.

VISION

Reach a remarkable position in the new Regenerative Medicine Industry.

VALUES

Innovation, ethics and quality.

Por que Cellpraxis?

Cell Therapy is already a reality



  • + Urinary Incontinence

  • + Neonatal Hypoxia

  • + Lipodystrophy

  • + Amyotrophic Lateral Sclerosis

CellPraxis® searchs for partners to perform React® phase II clinical trial in USA, looking for an IND submission to FDA. Click here to read more.

Products

  • ReACT®

Pipeline

  • Urinary Incontinence
  • Neonatal Hypoxia
  • Lipodystrophy
  • Amyotrophic Lateral Sclerosis

Contact

  • Contact Form
  • Rua Cincinato Braga, 122
  • Bela Vista, CEP: 01.333-010
  • São Paulo – SP
  • Tel.: +55 11 3814-1756